{"transactions":[{"id":791955,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Officer"}}],"security":"Common Stock","published_at":"2026-05-05T23:01:37.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":524,"price":9.03,"value":4731.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":22806,"source":{"system":"sec-edgar","filing":"0001193125-26-207031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000119312526207031/ownership.xml","form_type":"4"}},{"id":846445,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-12T20:58:25.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":105000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":105000,"derivative":{"exercise_price":10.19,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":105000},"source":{"system":"sec-edgar","filing":"0001193125-26-104384","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000119312526104384/ownership.xml","form_type":"4"}},{"id":846444,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-12T20:58:25.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":23330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting."}],"balance_after":23330,"source":{"system":"sec-edgar","filing":"0001193125-26-104384","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000119312526104384/ownership.xml","form_type":"4"}},{"id":1053737,"issuer":{"id":5215,"kind":"organization","name":"BridgeBio Oncology Therapeutics, Inc.","symbol":"BBOT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-28T20:34:54.000Z","date":"2025-08-26","kind":"grant","planned":false,"acquired":true,"shares":633570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying such option shall vest on July 21, 2026, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date."}],"balance_after":633570,"derivative":{"exercise_price":9.59,"expiration_date":"2035-08-25","underlying":"Common Stock","underlying_shares":633570},"source":{"system":"sec-edgar","filing":"0000950170-25-111986","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000095017025111986/ownership.xml","form_type":"4"}},{"id":1215351,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:57:50.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":130000,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0000950170-25-036685","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000095017025036685/ownership.xml","form_type":"4"}},{"id":1712799,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-13T21:05:19.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":75000,"derivative":{"exercise_price":14.42,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-23-070016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000095017023070016/ownership.xml","form_type":"4"}},{"id":1767950,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T20:17:27.000Z","date":"2023-10-01","kind":"grant","planned":false,"acquired":true,"shares":229634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest with respect to 25% of the total number of the underlying shares on September 11, 2024, and the remaining shares will vest in equal monthly installments over the following three-year period, such that the stock option will be fully vested on September 11, 2027, subject to the Reporting Person continuing to be a service provider to Issuer through each vesting date."}],"balance_after":229634,"derivative":{"exercise_price":12.73,"expiration_date":"2033-09-30","underlying":"Common Stock","underlying_shares":229634},"source":{"system":"sec-edgar","filing":"0001610717-23-000301","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000161071723000301/form4.xml","form_type":"4"}},{"id":1959075,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Performance Stock Unit","published_at":"2023-03-10T14:31:05.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":111111,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each performance-based restricted stock unit (\"PSU\") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":111111},"source":{"system":"sec-edgar","filing":"0001209191-23-017721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919123017721/doc4.xml","form_type":"4"}},{"id":1959074,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-03-10T14:31:05.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":165192,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-fourth of the options vested on September 15, 2022, and one-sixteenth of the options vest each quarter thereafter."}],"balance_after":0,"derivative":{"exercise_price":21.83,"expiration_date":"2031-09-14","underlying":"Common Shares","underlying_shares":165192},"source":{"system":"sec-edgar","filing":"0001209191-23-017721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919123017721/doc4.xml","form_type":"4"}},{"id":1959073,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Shares","published_at":"2023-03-10T14:31:05.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":181972,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects restricted stock units (\"RSUs\").  Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-017721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919123017721/doc4.xml","form_type":"4"}},{"id":1959072,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Shares","published_at":"2023-03-10T14:31:05.000Z","date":"2023-03-10","kind":"disposition_to_issuer","acquired":false,"shares":20724,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto.  Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the effective time of the Merger (the \"Effective Time\"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the \"Per Share Consideration\")."}],"balance_after":181972,"source":{"system":"sec-edgar","filing":"0001209191-23-017721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919123017721/doc4.xml","form_type":"4"}},{"id":2080025,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Shares","published_at":"2022-12-21T01:07:33.000Z","date":"2022-12-16","kind":"sale","acquired":false,"shares":2241,"price":26.75,"value":59946.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."}],"balance_after":202696,"source":{"system":"sec-edgar","filing":"0001209191-22-062257","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919122062257/doc4.xml","form_type":"4"}},{"id":2154235,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Shares","published_at":"2022-09-20T20:56:06.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":9243,"price":18.86,"value":174322.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold at prices ranging from $18.80 to $18.86. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":204937,"source":{"system":"sec-edgar","filing":"0001209191-22-050745","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919122050745/doc4.xml","form_type":"4"}},{"id":2294930,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Shares","published_at":"2022-04-19T20:52:15.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":111111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":214180,"source":{"system":"sec-edgar","filing":"0001209191-22-024788","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919122024788/doc4.xml","form_type":"4"}},{"id":2566316,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-09-17T20:31:00.000Z","date":"2021-09-15","kind":"grant","acquired":true,"shares":165192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the Common Shares underlying this option vest on September 15, 2022, and 1/16 of the Common Shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":165192,"derivative":{"exercise_price":21.83,"expiration_date":"2031-09-14","underlying":"Common Shares","underlying_shares":165192},"source":{"system":"sec-edgar","filing":"0001209191-21-056645","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919121056645/doc4.xml","form_type":"4"}},{"id":2566315,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":49677,"kind":"person","name":"Mehra Uneek","position":1,"cik":"0001881504","reported_name":"Mehra Uneek","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Shares","published_at":"2021-09-17T20:31:00.000Z","date":"2021-09-15","kind":"grant","acquired":true,"shares":103069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the Common Shares underlying the RSUs vest on September 15, 2022, and 1/16 of the Common Shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":103069,"source":{"system":"sec-edgar","filing":"0001209191-21-056645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1881504/000120919121056645/doc4.xml","form_type":"4"}}]}